Structural polymorphism of non-covalent peptide-based delivery systems: Highway to cellular uptake  by Deshayes, Sébastien et al.
Biochimica et Biophysica Acta 1798 (2010) 2304–2314
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamemReview
Structural polymorphism of non-covalent peptide-based delivery systems: Highway
to cellular uptake
Sébastien Deshayes, Karidia Konate, Gudrun Aldrian, Laurence Crombez, Frédéric Heitz, Gilles Divita ⁎
Centre de Recherches de Biochimie Macromoléculaire, CRBM-CNRS, UMR-5237, UM1-UM2, University of Montpellier, Department of Molecular Biophysics and Therapeutics,
1919 Route de Mende, 34293 Montpellier, France⁎ Corresponding author. Tel.: +33 4 67 61 33 92; fax
E-mail address: gilles.divita@crbm.cnrs.fr (G. Divita)
0005-2736/$ – see front matter © 2010 Elsevier B.V. A
doi:10.1016/j.bbamem.2010.06.005a b s t r a c ta r t i c l e i n f oArticle history:
Received 8 April 2010
Received in revised form 2 June 2010
Accepted 2 June 2010
Available online 10 June 2010
Keywords:
Cell-penetrating peptide
Drug delivery
Conformational versatility
Biological membrane
NanoparticleDuring the last two decades, delivery has become a major challenge for the development of new therapeutic
molecules for the clinic. Although, several strategies either viral or non viral have been proposed to favor
cellular uptake and targeting of therapeutics, only few of them have reach preclinical evaluation. Amongst
them, cell-penetrating peptide (CPP) constitutes one of the most promising strategy and has applied for
systemic in vivo delivery of a variety of therapeutic molecules. Two CPP-strategies have been described; using
peptide carriers either covalently-linked to the cargo or forming non-covalent stable complexes with cargo.
Peptide-based nanoparticle delivery system corresponds to small amphipathic peptides able to form stable
nanoparticles with either proteins/peptides or nucleic acids and to enter the cell independently of the
endosomal pathway. Three families of peptide-based nanoparticle systems; MPG, PEP and CADY have been
successfully used for the delivery of various biologically active cargoes both ex vivo and in vivo in several animal
models. This reviewwill focus on the mechanism of the peptide-based nanoparticles; PEP, MPG and CADY in a
structural and biophysical context. It will also highlight themajor parameters associated to particle formation/
stabilization and the impact of the carrier structural polymorphism in triggering cellular uptake.: +33 4 67 52 15 59.
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Table 1
Primary and secondary amphipathic peptides.
Peptide Sequence aa MW [Da] Ref.
MPG Ac-GALFLGFLGAAGSTMGAWSQPKKKRKV-Cya 27 2908.5 [22,23]
Pep-1 Ac-KETWWETWWTEWSQPKKKRKV-Cya 21 2907.4 [24]
CADY Ac-GLWRALWRLLRSLWRLLWKA-Cya 20 2653.0 [25]
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The recent deciphering of the human genome has provided new
insights for the development of novel therapeutic approaches.
Understanding genes and related proteins associated to their function
and their mechanism of regulation has allowed the design of new
potent molecules more speciﬁc for their targets. However, biological
membranes constitute impermeable barriers for this new generation
of bioactive molecules and although they exhibit potent activities,
their cellular internalization still remains a major challenge. In order
to overcome these limitations, several viral and non viral strategies
have been developed to improve cellular delivery of therapeutics.
Carrier peptides or cell-penetrating peptides (CPPs) represent a
promising approach opening new perspectives for drug delivery and
have undergone a real increase of interest during the last decade [1].
Although CPPs' deﬁnition is constantly evolving, they can be described
as short peptides of less than 30 amino acids which are usually
amphipathic, possess a positive net charge and are able to penetrate
biological membrane and to transfer cargoes into cells [2]. So far
numerous CPPs have been reported to favor the delivery of a large
panel of cargos from small particles to peptides, proteins and nucleic
acids into a wide variety of cell types and in vivo models [3,4]. Since
the ﬁrst deﬁnition of CPP and the groundwork established by Langel et
al. in 2002 [5], the ﬁeld of CPPs has signiﬁcantly evolved and major
rules and parameters have been deﬁned to classify a peptide as a CPP:
including peptide-secondary structure, uptake mechanism and the
cargo-related biological activity.
Although, the efﬁciency of CPPs is not questionable, themechanism
through which they allow the translocation of active cargo across
plasma membrane is still a matter of controversy and it remains
difﬁcult to establish general rule for their uptake mechanism. The use
of live cells togetherwith the identiﬁcation of endocytotic pathwaysby
combining new inhibitors has allowed a better characterization of the
CPP-internalization process and a re-evaluation of their cellular uptake
mechanism and of their direct translocation ability [6]. Several cellular
uptake mechanisms have been proposed for CPP; from direct
translocation [7–10] to endocytosis [11–13] aswell as the combination
of several pathways [14]. Considering that several parameters have
been implicated to control the cellular uptake pathway of CPP; their
structure, ability to interact with cell membrane components, the
nature of the cargo and the cell type, and mechanism should be
deciphered on a case-by-case basis [6,15–17].
CPP-uptake process is more complicated than it was expected
originally as peptide/lipid interactions have been shown not to be
sufﬁcient for the cellular uptake. The presence of negatively charged
residues in the peptide sequence seems to be essential for transloca-
tion by interacting with cell surface proteoglycan, receptor proteins as
well as with membrane potential. Therefore, a number of CPPs do not
directly interact with phospholipids and present a cellular uptake
mediated by endocytosis which is triggered by electrostatic interac-
tions with cell surface. Other CPPs have been demonstrated to actively
cross the cell membrane. In the latter case, evidence have been
reported that the CPP/phospholipid interactions and the peptide-
secondary structure play a major role in the cellular uptake
mechanism and the orientation of cell entry pathway [9,18]. From a
structural point of view, the importance of speciﬁc conformation of the
peptide, in membrane insertion originally proposed such as amphi-
pathic helical structure, seems now more associated to the concept of
conformational versatility or structural polymorphism [18–22].
CPPs can be subdivided into two main classes, the ﬁrst requires
chemical linkage with the cargo [23–26] and the second involves the
formation of stable, non-covalent complexes [26,29] both of them
were successfully used at preclinical or clinical levels[1,3,30]. The
non-covalent strategy is based on short amphipathic peptides that
form stable nanoparticles with cargoes without requiring any cross-
linking or chemical modiﬁcations [24,29,31]. This strategy has beenshown to constitute a potent alternative for drug delivery and offers
several advantages, including no requirement for chemical cleavage
which favor a better release of the cargo inside the targeted cells, and
facilitates modiﬁcations in order to increase speciﬁcity for the cargo
and/or the target.
The ﬁrst non-covalent CPP, MPGwas proposed in 1997 [32] for the
delivery of short nucleic acids, then the strategy was extended to
protein and peptide non-covalent cellular delivery by the develop-
ment of Pep-1 [33]. To date, three families of peptide-based-
nanoparticle (PBN) delivery system: MPG, PEP and CADY have been
developed [29]. MPG and PEP are primary amphipathic peptides,
combining hydrophilic domain together with a hydrophobic amino
acid rich motif [34]. CADY is a secondary amphipathic peptide which
adopts an α-helical conformation in the presence of lipids or siRNA,
thereby distributing the residues all along the helix that leads to form
distinct aromatic, hydrophobic and hydrophilic domains [21–35].
Cellular uptake mechanism of PBN is controlled by their structural
polymorphism, their ability to form stable nanoparticles with the
cargoes and to interact with membrane components. PBN mainly
enters the cell independently of the endosomal pathway and
efﬁciently deliver cargoes into a large variety of cell lines as well as
in animal models [25,29]. Non-covalent strategies for protein and
oligonucleotide delivery have been recently extended to other CPPs,
including TAT [28–36], poly-arginine [37,38], Transportan- [39],
Penetratin- [40] or TP10-derived peptides [41].
The present paper will be focused on the biophysical features of
peptide-based nanoparticle delivery systems and will review the
main common characteristics of MPG, Pep-1 and CADY carrier
peptides from the structural features to their ability to form
nanoparticles with different therapeutic cargoes. The impact of the
structural polymorphism on the cellular uptake mechanism of CPP
will be discussed.
2. Peptide-based nanoparticle families
Three different families of PBN have been developed, based on
either primary or secondary amphipathic peptides: MPG, PEP and
CADY. MPG and Pep-1 are primary amphipathic peptides consisting of
two distinct hydrophilic and hydrophobic domains (Table 1). The C-
terminal hydrophilic domain of both carriers is a lysine rich motif
which is derived from the nuclear localization sequence (NLS) of SV40
large T antigen (KKKRKV). This part is generally required for the
interactions with nucleic acids, intracellular trafﬁcking of the cargo
and to improve solubility of the carrier peptide. The N-terminal
hydrophobic domain differs between MPG and Pep-1. The hydropho-
bic motif of MPG is derived from the fusion sequence of the HIV
protein gp41 (GALFLGFLGAAGSTMGA) [32–35,42] and is required for
efﬁcient interactions with the cell membrane and cellular uptake. For
Pep-1, the hydrophobic part involves a tryptophan-rich motif derived
from the reverse transcriptase of HIV-1 (KETWWETWWTE), which
is also involved for efﬁciently targeting cell membrane and for
hydrophobic interactions with peptide or protein cargoes [33]. The
hydrophilic and hydrophobic parts are associated via a short linker
(WSQP) with a proline residue that keeps the ﬂexibility and the
integrity of both domains. CADY is a secondary amphipathic peptide
(GLWRALWRLLRSLWRLLWKA) derived from the PPTG1 peptide [43],
a variant of the fusiongenic peptide JTS1 [44]. CADY adopts a helical
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aromatic, a hydrophilic and a hydrophobic [35]. All peptide sequences
are acetylated at their N-terminus and bear a cysteamide group at
their C-terminus, both of which are essential for the stability of the
peptides and their transduction mechanism [45]. The cysteamide
function has been introduced into several peptide carriers as it offers
the advantage of being compatible with Fmoc synthesis and avoids
the use of cysteine, thereby protecting its side chain [32,42,46]. The
presence of cysteamide group at the C-terminus of the peptide
stabilizes both peptide/cargo and peptide/phospholipid interactions
and favors the formation of homogenous nanoparticles throughout
peptide disulﬁde bridges. Several variants of MPG and Pep-1 peptides
have been proposed to either favor interaction with speciﬁc cargoes
and/or to improve in vivo cargo delivery and selective targeting
[35,47].
3. Carrier/cargo interactions and formation of peptide-based
nanoparticles
MPG, Pep-1 and CADY were designed to transfer different cargoes
(nucleic acids, plasmid DNA, short oligonucleotides, siRNA, proteins
and peptides) into cells in a non-covalent manner. MPG strongly
interacts with charged molecules whereas Pep-1 is more appropriate
for protein/peptide and neutral DNA mimic molecules [27,48]. CADY
is less selective for one type of cargo and forms stable particles with
both charged and uncharged molecules [35,49]. These peptides
exhibit high afﬁnity in the nanomolar range and associate rapidly in
solution with their respective cargoes through non-covalent electro-
static or hydrophobic interactions. They all form stable non-covalent
nanocomplexes with their cargo that can be used both in cultured
cells and in vivo [25]. Thus understanding the nature and the
parameters which control the carrier/cargo interactions is essential
to standardize formulations and generally required to combine
several biochemical and biophysical technologies.
3.1. Formation of MPG/DNA complexes
MPG promotes the internalization of different types of nucleic
acids from plasmid DNA to small oligonucleotide (antisense, siRNA)
[32,41,45,50]. The formation of MPG/DNA nanocomplex involves
mainly electrostatic interactions between phosphates of nucleic acids
and charged residues of the peptide (arginine and lysine). It has been
characterized by gel shift assays and by ﬂuorescence spectroscopy,
monitoring changes either in the tryptophan intrinsic MPG-ﬂuores-
cence in the presence of nucleic acid or in ﬂuorescently labeled-
oligonucleotide upon binding of MPG [48]. As reported in Fig. 1A,
titration of a ﬂuorescently labeled-antisense oligonucleotide (18-mer)
by increasing concentration of MPG results in an important quenching
of ﬂuorescence, with saturation occurring for a ratio of about 7
peptides per oligonucleotidewhich corresponds to a positive/negative
charge ratio of 2 [48]. Determination of the equilibrium constants from
both experiments indicates that MPG exhibits high afﬁnity for
oligonucleotides (Kd of about 6-5 nM). Similar results were obtained
by gel shift assays, showing that over a peptide/oligonucleotidemolar
ratio of 7/1 and a peptide/plasmid DNA charge ratio of +2, no free
form of the nucleic acid is detected and the amount of complex unable
to enter the gel is signiﬁcantly increased. In addition anisotropy
measurements led to the same results and identical molar and charge
ratio, asﬂuorescence anisotropy is directly correlated to changes in the
size of the particles (Fig. 1A). All together, these data indicated a strong
interaction between MPG and the oligonucleotide cargo to form non-
covalent stable MPG/oligonucleotide complexes. Further character-
ization of these complexes by both light scattering measurement and
scanning electron microscopy has revealed the presence of stable
homogenous nanoparticles of 100 nm diameter [50].3.2. Formation of CADY/siRNA complexes
CADY forms stable nanoparticles with siRNA, that mainly involved
electrostatic interactions between Arg/Lys of CADY and phosphate
group of the siRNA [21]. The ability of CADY to interact with siRNAwas
investigated by agarose gel shift assays and ﬂuorescence spectroscopy.
A siRNA (21-mer) targeting glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) has been used as reference for both in vitro and in cellulo
measurements. Results demonstrated that complex formation is
initiated at a low molar ratio of CADY/siRNA (1/1), and that siRNA
molecules are entirely associated with CADY at a molar ratio of 15/1.
However, that higher molar ratio≥40/1 is required to obtain a strong
biological response in cultured cell suggests that CADY is able to
form high-molecular weight complexes or aggregates, as previously
described forMPG. The formation of non-covalent complexes was also
studied by steady-state ﬂuorescence spectroscopy and ﬂuorescence
anisotropy. The four Trp residues of CADY constitute excellent internal
probes to monitor the interaction with siRNA. The binding of siRNA to
CADY induced 42% quenching of ﬂuorescence, together with a 7-nm
blue shift of the emission spectrum from 345 to 338 nm. Binding
saturation was achieved at molar ratio ranging between 5/1 and 10/1
and CADY dissociation constant for siRNA was estimated at 15 nM,
revealing that several molecules of CADY interact with high afﬁnity
with one siRNA molecule [35]. CADY/siRNA interaction has also been
followed using a FITC-labeled siRNA. Binding of CADY to siRNA
induced 80% quenching of extrinsic ﬂuorescence, with saturation
achieved for a peptide/siRNA molar ratio of about 10/1 (Fig. 1B) [21].
In addition, ﬂuorescence polarization of the FITC-siRNA clearly
increased with peptide concentration, revealing a direct correlation
between changes in ﬂuorescence and the formation of CADY/siRNA
particles. Taken together, these data are consistent with the tight
interaction between CADY and siRNA and the formation of a particle of
peptides surrounding the siRNA [21].
3.3. Formation of Pep-1/protein complexes
Pep-1 carrier was mainly designed to improve translocation of
proteins and peptides through the plasma membrane [33]. Pep-1 is
able to form nanocomplexes with different cargoes by a combination
of hydrophobic and hydrophilic interactions. The ability of Pep-1 to
interact with several cargoes has been investigated by ﬂuorescence
spectroscopy and size exclusion chromatography. The binding of a 32-
mer peptide (P-A) cargo to Pep-1 induced a marked quenching of the
intrinsic tryptophan ﬂuorescence (36%), associated with a 11 nm blue
shift of the ﬂuorescence emission maximum (from 350 to 339 nm),
suggesting that the Trp residues of Pep-1 interact directly with
the cargo. Data analysis has revealed that more than one molecule of
Pep-1 strongly interacts with P-A with a dissociation constant in the
range of 120–150 nM. That the interaction between Pep-1 and P-A
remains stable at high salt concentrations (300 mM NaCl), revealing
that Pep-1 associated rapidly with cargo into non-covalent stable
complexes mainly through hydrophobic interactions. Similar results
were obtained with several distinct cargoes indicating that Pep-1
binding is not speciﬁc for a given peptide [33,51]. Finally analysis of
the nanoparticles complexes obtained with Pep-1 by both light
scattering and scanning electron microscopy has revealed that Pep-1/
cargo complexes consist in globular nanoparticles with size in the
range of 100–200 nm (Fig. 1C and D) [52].
4. Structural features of MPG, Pep-1 and CADY
Although, the structural behavior of CPPs is well documented, the
impact of their conformation on the ability to enter the cell and to
deliver drug remains unclear. For both primary and secondary
amphipathic peptides, conformational versatility has been reported
to be crucial for cellular uptake efﬁciency. MPG, Pep-1 and CADY
Fig. 1. Formation of peptide carrier/cargo nanocomplexes. (A) Variation of the relative ﬂuorescence (maximum of the emission spectrum) (●) and of the corresponding ﬂuorescence
anisotropy (○) of HEX-labeled-bcl2 oligonucleotide (solution containing 10 nmol) as a function of the amount of MPG peptide. (B) Variation of the relative ﬂuorescence (maximum
of the emission spectrum) (●) and the corresponding ﬂuorescence polarization (○) of FITC-labeled CycB1 siRNA (solution containing 200 nmol) as a function of the amount of CADY
peptide. (C) Micrograph of typical Pep-1/cargo nanoparticles at ratio 20/1. The cargo was the tumour suppressor protein p27Kip. (D) The corresponding distribution of particle size.
Pep-1/p27Kip complexes were formed in water, spotted onto an intermetallic substrate and examined by scanning electronmicroscopy using a JEOL6500F instrument equipped with
a ﬁeld emission tip and operated at 7 KeV. [Adapted from [52]].
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environment and upon binding to their speciﬁc cargoes (oligonucleo-
tides, proteins, peptides, siRNA…) [21,48,51].
4.1. Conformation of carrier peptides in solution
The structural plasticity of MPG, Pep-1 and CADY was analyzed by
a combination of different spectroscopic methods. Circular dichroism
(CD) investigation has revealed that these carriers share a common
mainly disordered conformation at low concentration in solution
(Fig. 2A). In water or phosphate buffer, MPG exhibits a CD spectrum
with a single minimum at 198 nm, a characteristic of a disordered
structure, independent of the concentration of peptide [48]. CD
proﬁles of CADY obtained in water are composed of a single minimum
at 203 nm, indicative of mainly random coil conformations whatever
the concentration of peptide used [21]. However the higher position
of the single minimum (203 nm instead of 198 nm) associated to a
slight deviation around 220 nm suggests the contribution of residual
helical secondary structure to the CD spectrum (Fig. 2A). Pep-1
displays a slightly similar structural behavior than CADY in water.
However while no concentration effects occurred for MPG and CADY
structure, increasing Pep-1 concentration up to 3 mg/ml induces ahigh propensity of the peptide to fold into an α-helix. Moreover, the
folding or Pep-1 into an α-helix at high concentration was conﬁrmed
by FTIR and NMR spectroscopy analyses [51].
4.2. Membrane mimicking environment triggers peptide folding
Structural studies of the peptides in the presence of membrane
mimicking environment have been investigated by combining several
spectroscopic methods, using different types of solvents or liposomes.
In the presence of phospholipid vesicles, peptide-based-nanoparticles
undergo a structural transition from a disordered state to a speciﬁc
secondary structure. Although MPG, Pep-1 and CADY seem to have a
similar versatility, their conformational states strongly differ within
membranes. In the presence of phospholipid vesicles or SDS, MPG has
a net tendency to fold into a β-sheet structure [48]. The existence of a
sheet structure as the major structural component of MPG was
conﬁrmed by FTIR with the existence of a major Amide I band around
1625 cm−1 associated with a broad shoulder at 1655 cm−1, in the
presence of phospholipids [53]. FTIR and CD experiments have
pointed out an α-helical conformation for Pep-1 in the presence of
lipids. CD spectra exhibit two minima at 206 and 222 nm and one
maximum around 190 nm, indicating that helical structure is the
Fig. 2. Structural analysis of MPG, Pep-1 and CADY by circular dichroism spectroscopy.
(A) CD spectra are recorded for MPG, Pep-1 and CADY at 75 µM in their free form in
water. (B) CD spectra are recorded for CADY at 75 µM in its free form (blue) and in the
presence of pure DOPG vesicles at several different lipid/peptide ratios (black
dashed) until a 10/1 ratio (red). Mean molar ellipticity per residues is expressed in
deg cm2dmol−1.
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characterized by NMR spectroscopy in the presence of SDS, the NOEs
reveal an α-helix motif for residues 4 to 13 and NOEs detected at the
beginning of the sequence were indicative of a 3-10 helix motif. The
distribution of residues throughout the helix leads to the formation of
a tryptophan cluster that favors interaction with cargoes [51].
CADY adopts a straightforward α-helix conformation in the
presence of lipid vesicles, with typical CD spectra exhibiting two
minima at 207 nm and 222 nm and one maximum around 190 nm,
suggesting that the liposomes induce a structural transition of CADY,
from random coil to an α-helical conformation (Fig. 2B). In addition
molecular modeling constructs indicated that the helical folding
induces a segregation of the hydrophobic, aromatic, and hydrophilic
domains as expected by the design of the secondary amphipathic
peptide [35]. In general, for the three families of PBN; MPG, Pep-1 and
CADY peptide/lipid interactions involve electrostatic forces and their
structural transitions are more pronounced in the presence of
negatively charged liposomes than with zwitterionic vesicles
[21,48,51].
AlthoughMPG, Pep-1 and CADY have a similar ﬂexibility and adopt
a speciﬁc conformation in the presence of liposomes, MPG and Pep-1
conformational plasticity slightly differs from that of CADY. Indeed
they are both primary amphipathic peptides that possess the same
hydrophilic C-terminal domain; i.e. the nuclear localization sequenceof the SV40. CD and NMR analyses of Pep-1 and MPG showed that the
NLS domain is disordered and has no speciﬁc conformation with
phospholipids [54]. Thus, both MPG and Pep-1 adopt a speciﬁc
secondary structure only in their N-terminal domain in the presence
of liposomes, whereas CADY is able to fold into a helix throughout the
sequence [21].
4.3. Conformational analyses in the presence of respective cargoes
MPG, Pep-1 and CADY form stable nanoparticles with their res-
pective cargoes (oligonucleotides, proteins, peptides and siRNA…).
These complexes are stabilized by a combination of electrostatic and
hydrophobic interactions between the carrier and the cargo and also
by cargo-mediated secondary structure changes of the peptide.
Analysis of the inﬂuence of the respective cargoes on the structural
behavior of MPG and CADY have revealed that both peptides are able
to adopt a speciﬁc secondary structure in the presence of oligonucle-
otide and siRNA, respectively [48,51]. The addition of an oligonucle-
otide to a solution of MPG for a peptide/cargo ratio of 20/1 promotes
structural transition of the peptide from random coil to β-sheet
structure, which is further increased by the addition of lipid vesicles
[48]. Binding of CADY to siRNA at a peptide/cargo ratio of 20/1 results
in a change in the CD spectrum, indicative of an increase in α-helical
contributions combined to a decrease in the amount of unfolded
peptide, then as observed for MPG, intensity of the helical spectral
contribution is enhanced in the presence of lipids [21]. In contrast, to
MPG and CADY, no modiﬁcation of Pep-1 secondary structure was
observed in the presence of different peptide cargoes and only the
presence of lipid vesicles induced changes in the secondary structure
of Pep-1 engaged in the complex [51].
5. Interactions of PBNwithmembrane andmembranes components
Cellular membrane constitutes by its physico-chemical properties
one of the main barriers to the use of large therapeutic molecules in
the cultured cells and in vivo. Therefore, understanding the para-
meters that control and triggermolecule/CPP/membrane interactions
is a major question to address in order to optimize their cellular
uptake. Several technologies can be combined to investigate mole-
cule/membrane and CPP/membrane interactions [55,56]. Although
artiﬁcial membranes cannot be considered as physiological mem-
branes, they constituted potent tools to investigate the mechanism of
membrane insertion of CPPs, together with their ability to form stable
complexes with phospholipids. In the last decade, membrane tech-
nology has signiﬁcantly evolved and offers now the possibility of
using mixture of different phospholipids with composition mimicking
physiological membranes and the choice of constituting lipid or lipid/
protein membrane micro domains or rafts. Therefore, the use of
artiﬁcial membrane has a major impact on understanding CPP cellular
uptake when the mechanism required direct interaction with
membrane phospholipids. Intrinsic amphipathic feature of peptides
and their insertion into phospholipid monolayers can be analyzed by
surface physic methods using monolayer approaches. The ability of
peptides to interact with liposomes can be monitored following
changes of their intrinsic tryptophan ﬂuorescence in the presence of
small unilamellar vesicles. By combining these different methods, we
have identiﬁed intrinsic properties of the amphipathic MPG, Pep-1
and CADY peptides in membrane mimicking condition.
5.1. Adsorption at the air/water interface: amphipathicity
The amphipathicity of MPG, Pep-1 and CADY was evaluated by
surface physic experiments using the monolayer approach [57,58].
The surface pressure induced by adsorption of peptides at the air/
water interface was recorded in function of the concentration of
peptides injected in the subphase. Then saturating surface pressure
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concentration of peptide. This study revealed that CADY is more
amphipathic than MPG and Pep-1, the latter displaying a poor afﬁnity
for the interface (Fig. 3A). Comparison of the saturating pressure
(πsat) indicated that CADY is by far the most amphipathic peptide
(πsat=30 mN/m) while Pep-1 is the less one (πsat=5 mN/m)
[21,51,53]. In addition, MPG and CADY displayed a similar critical
micellar concentrations (CMCs) with values of 250 nM and 230 nM,
respectively, while that of Pep-1 is slightly higher (500 nM). Taken
together, these results emphasize that Pep-1 has a weaker amphi-
pathic character than CADY and MPG, which is not surprising
considering that the N-terminus tryptophan-rich domain of Pep-1
does not correspond to a classical hydrophobic segment.
5.2. Insertion into phospholipid monolayers
The ability of MPG, Pep-1 and CADY to insert into phospholipid
monolayers spread at the air/water interface was monitored by
measuring variations in surface pressure (Δπ) using different lipid
ﬁlms with distinct initial surface pressures (πi) and by injecting a
given peptide concentration in the subphase [59]. The penetration
curve, corresponding to the variations of surface pressure (Δπ) inFig. 3. Afﬁnity for air/water and interactions with membranes. (A) Adsorption measurement
a subphase solution constituted of a 0.154 MNaCl buffer. Adsorption curves allow the identiﬁ
of CADY into phospholipids monolayer. The penetration curves are reported for CADY into D
MPG into phospholipid bilayers. The intrinsic ﬂuorescence of the tryptophan of MPG is
phospholipid bilayers. The ﬂuorescence of the ﬁve tryptophan of Pep-1 is monitored upon a
quoted on the inset which shows the variation as a function of the peptide/lipid ratio of the w
[48,51]].function of the initial surface pressure (πi), allows the extrapolation of
the critical pressure of insertion (CPI) (πi for Δπ=0) reﬂecting the
insertion of peptides into phospholipid monolayers [59]. Penetration
experiments were carried out using various phospholipids with
headgroups of different natures (zwitterionic or negatively charged)
and in different physical state (liquid expanded or liquid condensed).
The examination of the variation of surface pressure measured for an
air/water interface at low lipid content (Δπ for πi=0) provides
information on the interactions occurring between the peptide and
the phospholipids. That CPI values are higher than those obtained
for the pure peptides at saturation (πsat) indicating that CADY/MPG/
Pep-1 peptides strongly interact with phospholipids in membrane
monolayers and a spontaneous insertion of the peptide into natural
membrane [53,57]. CPI value for MPG increases from 13 mN/m to 30
and 38 mN/m for DPPC and DPPG, respectively. In the case of liquid
expanded monolayers, CPI values of 48 mN/m and 33 mN/m were
obtained for DOPG and DOPC, suggesting a better uptake of MPG by
negatively charged phospholipids and that MPG insertion depends on
both the initial conformational state of the peptide and the nature of
the phospholipid headgroups. Pep-1 induces a strong increase in the
surface pressure of liquid expanded monolayers. Both DOPC and
DOPG yielded identical CPI (45 mN/m) and extrapolation at zeros of amphipathic peptides. CADY (black), MPG (grey) and Pep-1 (white) are tested with
cation of πsat of Pep-1 (5 mN/m), MPG (13 mN/m) and CADY (30 mN/m). (B) Insertion
OPC (Δ), DOPG (○), DPPC (▲) and DPPG (●) phospholipids monolayer. (C) Insertion of
monitored upon addition of POPG phospholipid vesicles. (D) Insertion of Pep-1 into
ddition of liposomes of DOPG. The various spectra correspond to the peptide/lipid ratio
avelength corresponding to the maximum of the ﬂuorescence emission. [Adapted from
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respectively) signiﬁcantly higher than that measured in the absence
of lipid (πsat). For the liquid condensed monolayers (DPPC and DPPG),
the CPI values are also relatively high whatever the nature of the head
groups (33 mN/m), suggesting that Pep-1 strongly interacts with all
phospholipids and spontaneously inserts into biological membranes
[51].
Similarly, CADY exhibits a strong afﬁnity for both air/water
interface and phospholipids. The presence of phospholipids in the
liquid expanded states (DOPC and DOPG) at low initial pressure
signiﬁcantly decreases the CMC of CADY from 230 nM to 180 nM for
DOPC and to 100 nM for DOPG, highlighting strong interactions
between CADY and phospholipids [21]. A similar CPI value of 40–
42 mN/m was obtained for DOPC, DOPG and DPPG revealing a
spontaneous insertion of CADY in phospholipid monolayers irrespec-
tive of the nature of head groups (Fig. 3B). Moreover, extrapolated
surface pressure for zero initial pressure (Δπ=40 mN/m for πi=0)
are higher than those observed for the free peptide at saturation
(πsat=30 mN/m) (Fig. 3B), conﬁrming tight interactions between
CADY and the different phospholipids. In the case of the liquid
condensed DPPC, CADY inserts with a high CPI value (∼36 mN/m) but
the value of surface pressure at low initial pressure (24 mN/m)
indicates moderate CADY/DPPC interactions.
5.3. Insertion into phospholipid bilayers
The insertion of MPG, Pep-1 and CADY into phospholipid bilayers
has been investigated by ﬂuorescence spectroscopy. MPG, Pep-1 and
CADY contain one, ﬁve and four Trp residues in their sequences,
respectively, which constitute sensitive probes to monitor interaction
with phospholipids and changes in the peptide environment upon
penetration into phospholipid bilayers. Binding of MPG, CADY or Pep-
1 peptides to phospholipids induced a drastic modiﬁcation of their
ﬂuorescence emission associated to a blue shift of themaximumof the
Trp-ﬂuorescence emission from 348/350 nm to 328/330 nm depend-
ing on the peptides. The shift of ﬂuorescence emission reveals a switch
in the Trp residue environment from polar to apolar in the presence of
phospholipid vesicles and indicates that the tryptophan domain of the
peptide is embedded in the phospholipid bilayer (Fig. 3C). The change
in MPG-emission wavelength is associated to an increase in the
ﬂuorescence intensity, whereas for Pep-1 it is accompanied by
quenching of ﬂuorescence [51]. These observations suggest that
Pep-1 tryptophans are embedded in the lipidic core and that
ﬂuorescence energy transfer occurs between Trp residues organized
in cluster when Pep-1 adopts a helical structure (Fig. 3D). The
interaction between CADY and phospholipid vesicles also results in a
marked change in the environment of Trp residues from polar to
nonpolar, characterized by a Trp-ﬂuorescence emission blue shift of
17 nm and 13 nm, associated to a 1.8 and 2.0 fold enhancement of
ﬂuorescence intensity, in the presence of DOPG and DOPC vesicles,
respectively. Both DOPC and DOPG liposomes induced ﬂuorescence
emission shift with a saturation occurring for a similar lipid/peptide
molar ratio (ca: 3), which conﬁrmed that the nature of phospholipid
head groups has no inﬂuence on the ability of CADY to insert into
phospholipid mono- and bilayers [21].
5.4. Interaction with cell surface proteoglycan
Before reaching the phospholipid part of the plasma membrane,
the carrier/cargo complex (PBN/cargo) needs to deal with compo-
nents of the extracellular matrix such as proteoglycans, which are
playing a critical role in the internalization of external molecule [60].
It is now well admitted than the ﬁrst step of the CPP mechanism
corresponds to electrostatic interactions with cell surface proteogly-
can (GAGs), resulting in a clustering at the cell surface which triggers
activation of intracellular signals/actin remodeling and cell entrythroughout numerous distinct pathways involving either direct
translocation or endocytotic processes [61–63]. Therefore investiga-
tion of the interaction between CPPs and heparan sulfate is also a
major piece of the puzzle to consider. The ability of MPG and CADY to
interact with proteoglycan has been investigated by gel shift
experiments. In order to study the impact of GAG on the stability of
MPG/DNA and CADY/siRNA complexes, MPG was associated, in
water, with an 18-mer oligonucleotide at a charge ratio of 5, and CADY
with a siRNA at different charge ratios at which the complexes have
been shown to be highly stable [21,48,64]. Complexes were then
incubated in the presence of increasing amounts of several soluble
GAGs, including heparin, dextran sulfate and hyaluronic acid, which
have different numbers of sulfate groups per disaccharide unit and
both complex integrity and stability were analyzed by electrophoresis
on agarose gels (Fig. 4A). The presence of heparin or dextran sulfate,
both sugars bearing a high density of negative charges, induced a GAG
concentration-dependent dissociation of the complexes resulting in
migration of free DNA or siRNA into the gel. In contrast, hyaluronic
acid, which has a low charge density and no sulfate group, had no
effect on complex stability. The results strengthened the major
implication of electrostatic interactions within the MPG/ or CADY/
oligonucleotide nanoparticles. Complex dissociation is dependent on
the concentration of GAG but also on the MPG/DNA or CADY/siRNA
molar ratio. CADY/siRNA complexes at molar ratio of 40/1, which
corresponds to complex used on cultured cells and in vivo, remained
highly stable in the presence of high concentrations of GAG [21].
These results indicate that MPG and CADY peptides can interact with
negatively charged GAG, a major component of proteoglycans of the
cell surface and extracellular matrix, interactions which probably, as
for many other delivery systems, allow the binding of the complex
and its accumulation at the cell surface. Then peptides or complexes
which exhibit a high afﬁnity for phospholipids will be able to dive into
the cell membrane. The fact that high concentration of negatively
charged GAG affects the stability of the MPG/cargo and CADY/siRNA
complexes, pointed out the importance of the integrity of the PBN for
cellular and in vivo applications [64].
5.5. Membrane potential plays a major role in PBN cellular uptake
The membrane potential (or transmembrane potential) plays a
major role in cellularmembrane integrity and canmodulate or control
the internalization of a molecule through the plasma membrane.
Membrane potential corresponds to the electrical potential difference
between the cytoplasm of the cell and the culture medium. Moreover
membrane potential has also been reported to control endosomal
escape [65], thus the inﬂuence of the membrane potential and its
associated voltage dependence are additional parameters to consider
as they have already been reported to affect cellular uptake of several
CPPs [66,67]. These parameters were studied for primary amphipathic
peptides MPG and Pep-1 using either Xenopus oocytes or artiﬁcial
lipid bilayers.
The application of a solution of free peptides to voltage-clamped
oocytes induced marked increases in membrane conductance.
Increases were detected from the variation in membrane currents
recorded during voltage ramps applied from −80 mV (the usual
holding potential) to +80 mV and from −40 mV to +40 mV as
shown for MPG in Fig. 4B. The reversal potential for the peptide
induced current was close to−8 mV and−12 mV for Pep-1 and MPG
respectively, values which are similar to what has already been found
for other pore-forming peptides selective for monovalent cations [68].
With regard to the cargoes (oligonucleotide for MPG and peptide Pep-
A for Pep-1), the variations in membrane conductance induced by the
nanoparticle are slightly different. While the addition of free peptide
Pep-A and free oligonucleotide has no effect on the voltage ramps
(Fig. 4B and C), the association with Pep-1 and MPG did not affect the
reversal potential (−8 mV and −12 mV) but appears to reduce the
Fig. 4. Interactions with heparan sulfate and inﬂuence of membrane potential. (A) Interaction of MPGwith HSPGs. MPG peptide (1.8 μmol) was incubated in water with 100 pmol of
an 18-mer oligonucleotide in a “+/−” charge ratio of 5. After 30 min of incubation, increasing concentrations of heparin, dextran sulfate or hyaluronic acid were added to the
complexes. Samples were analyzed by electrophoresis on a 1% agarose gel, stained with ethidium bromide and revealed by UV illumination. (B) Effect of MPG on voltage-clamped
oocytes. Oocyte membrane currents were recorded during 450 ms long voltage ramps applied from a holding potential of−40 to +40 mV, every 5 s. Addition of a 10 µM solution
of MPG and MPG/oligonucleotide (10/1) complexes directly to the recording chamber induced a marked increase in membrane conductance that developed after 5–10 s.
(C) Macroscopic current–voltage (I–V) curves measured during application of a 10 µM solution of Pep-1, Pep-1/Pep-A (5/1) complexes and Pep-A on voltage-clamped oocytes using
a voltage-ramp from −40 to +40 mV. The current is shown after digital subtraction of leak current recorded before solution application. (D) Macroscopic current–voltage (I–V)
curves of MPG (10−7 M) in an azolectin bilayer (above) and single channel events induced by MPG (10−10 M) in a POPC/DOPE/DOPG (7:3:1, v/v/v) lipid bilayer for an applied
voltage of−143 mV (below). Recordings were performed in KCl 1 M, buffered with 10 mM HEPES (pH 7.4) with a digitization rate of 3000 Hz and a ﬁlter of 300 Hz. [Adapted from
[51,64]].
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whether this decrease in the current arises from an artiﬁcial decrease
of the peptide concentration because it is engaged in the complexes,
or to modiﬁcation of the transmembrane current characteristics. Both
hypotheses will explain the fact that complex formation signiﬁcantly
reduced and even totally abolish the toxicity of the peptide carrier. In
order to better understand the membrane potential dependence of
the peptide cellular uptake, artiﬁcial lipid bilayers were used to detect
macroscopic currents and single channel events. Peptides were
incorporated into azolectine planar lipid bilayers according to the
Montal–Mueller technique [69]. Macroscopic recording revealed net
I–V curves suggesting voltage dependence (Fig. 4D). In addition,
single channel events were identiﬁed for lower concentrations than
those used for macroscopic experiments (Fig. 4D). Taken together,
these results suggested the formation of small but signiﬁcant voltage-
dependent pore-like structures [9] and that the permeabilizingproperty of MPG and Pep-1 is associated to the formation of
membrane transient ion channels [9,48,51]. Finally, it should be
mentioned that such a condition, which gives rise to transmembrane
currents, does not generate propidium iodide cellular internalization
conﬁrming the lack of cytoxicity associated to MPG or Pep-1 cellular
uptake.
6. Model for the translocation process of carrier/cargo complexes
The development of new carrier peptides is often limited by a poor
understanding of the features required for their efﬁciency. Although
the use of several approaches allows the identiﬁcation of speciﬁc
properties, it is still hard to know how to combine most of them to
conceive a clear model for the translocation process [34]. The PBN;
Pep-1, MPG and CADY have been shown to signiﬁcantly improve the
delivery of different types of cargoes both in cultured cells and in vivo.
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cargo-mediated active biological response is independent of the
endosomal pathway. We demonstrated that PBN cellular uptake and
cargo-mediated biological response are not affected by the presence
of inhibitors of the endosomal pathways as well as by heparin or
trypsin treatments [21,29,45,64]. PBN tightly binds phospholipids,
induces cell membrane alteration and remodeling of the actin
network [21,64]. However, we cannot exclude that binding to the
cell surface of PBN–cargo complexes induces the formation of
vesicles that are rapidly destabilized thanks to the amphipathic
property of the PBN. By combining cellular observation together with
structural and biophysical investigations of the different peptides we
can propose the following model for the cellular internalization
mechanism of non-covalent MPG/Pep-1/ or CADY/cargo complexes.
The carrier peptides MPG, Pep-1 and CADY shared a number of
common properties that favored and drove the cellular uptake
pathway.
− The peptides form highly stable nanoparticles with their respec-
tive cargoes and strongly interact with phospholipid monolayers
or bilayers, mainly throughout electrostatic interactions.
− CADY/Pep-1 and MPG exhibit a marked structural polymorphism.
Their free forms are mainly unfolded in solution, whereas they all
adopt a speciﬁc secondary structure, folding into a β-sheet (MPG) orFig. 5.Model for the formation and cellular internalization of MPG/oligonucleotide, Pep-1/p
(1) electrostatic and hydrophobic interactions between carrier and cargo initiate a partial he
complex are stabilized by peptide/peptide interactions, corresponding to carrier-peripheral
and then (4) interaction with phospholipids; (5) insertion into cell membrane mediated byan α-helix (Pep-1 and CADY) upon interaction with phospholipids.
Similarly, in thepresenceof cargo, theypartially folded into aβ-sheet
(MPG) or an α-helix (CADY), structures which are enhanced when
peptide/cargo complexes interact with phospholipids.
− The carrier peptides whether associated or not with a cargo,
induce a voltage-dependent membrane permeability (Pep-1 and
MPG).
According to both structural and biophysical investigations, the
combination of the different properties identiﬁed for MPG, Pep-1 and
CADY led to a six-step mechanism (Fig. 5). This model involves ﬁrst
electrostatic and hydrophobic interactions between carrier and cargo
which induce a partial folding of peptide followed by the formation of
the core of the complex (1). Carrier/cargo complexes are stabilized by
peptide/peptide interactions that constitute the surface carrier-
peripheral (2). Electrostatic interactions of carrier/cargo complexes
with cell surface proteoglycan (3) initiate the interaction with
phospholipids (4) and then insertion into cell membrane mediated
by the carrier-peripheral (5). Finally, insertion of the complexes into
the membrane is associated to both peptide conformational transition
and membrane potential, which induces membrane structure pertur-
bations and leads to the release of the core complex into the cyto-
plasmic side, followed by the nuclear targeting or cytosolic release
depending on the carrier used (6).rotein and CADY/siRNA nanoparticles. The model consists of six steps corresponding to
lical or β-strand folding of peptide and form the core of the complex; (2) carrier/cargo
; (3) electrostatic interaction of carrier/cargo complexes with cell surface proteoglycan
the carrier-peripheral and (6) release into the cytoplasmic side of the core complex.
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There is still a long way to go, before understanding fully the
mechanism by which CPPs cross the plasma membrane and deliver
several drugs to their speciﬁc targets. However, during the last two
decades, we have witnessed a net increase in the number of
approaches to decipher the cellular uptake of CPPs and the com-
bination of a large set of biophysical studies had rendered possible the
identiﬁcation of crucial features required for the peptide carrier
activity. We have proposed a new generation of delivery system, the
peptide-based-nanoparticles, that offers an interesting alternative for
the delivery of different cargoes throughout a non-covalent strategy
[29]. The leader peptides Pep-1, MPG and CADY, have been shown to
mainly enter cells independently of the endosomal pathway and to
efﬁciently deliver cargoes into cells as well as in vivo. The biophysical
characterization of these three carriers and of their interaction with
cargoes has revealed that they share common properties leading to a
model for the mechanism of internalization of the carrier/cargo
particles. Although this model merge most of conformational and
interaction parameters, some points still remain to be clariﬁed. Other
CPPs covalently used, have also been reported entering the cell by a
non-endosomal mechanism, but only when high concentrations of
CPP-cargo are applied to the cell surface [70]. In contrast, the
organization of PBN–cargo in nanoparticle exposes several peptides
at their surface creating, even at a low concentration of particle, a high
local clusterization of CPPs able to interact with phospholipids and to
induce membrane reorganization. During the ﬁrst step of the
internalization process, CPPs will encounter heparan sulfate proteo-
glycans (HSPGs) that can induce endocytotic processes such as
macropinocytosis [16] or increase in membrane-ﬂuidity allowing
direct translocation of peptides [64]. Interaction triggers clusterization
of peptide at the cell surface, which then interacts with the lipid phase
of the membrane and favors cellular uptake. Most of the CPPs are
unable to overcome the energetic barrier to cross the phospholipid
bilayers and remain trapped in the endosome. The polymorphism of
MPG, Pep-1 and CADY is a structural feature closely related to their
delivery abilities as also reported for other carrier peptides such as
Transportan and TP10 [18,22]. Interestingly, in the case of PBN–cargo
complexes, the energetic barrier can be compensated by the structural
polymorphism of the peptide and its potency to interact with cellular
membrane which will control the cellular uptake mechanism [71].
In comparison to other CPPs, PBN–cargo particles need to be
sufﬁciently stable in physiological conditions in order to cross the
plasma membrane and reach the cytosol but, at the opposite; these
particles should also be able to disassemble inside the cell in order to
release the therapeutic cargo. Indeed the cytosolic release or decaging
process of the particles needs more investigation and parameters such
as the association/dissociation constants and thus the particle stability
should be considered. Both size and homogeneity of the nanoparticles
are dependent on the carrier/cargo ratio and optimal protocols for
transduction have been described for carrier/cargo ratio of about 10/1
to 15/1 depending on the nature of the cargo. One of the advantages of
non-covalent strategy resides in the possibility of modiﬁcation of the
surface peptide layer of the particle in order to stabilize the particle
for systemic in vivo administration or for targeting that will open
interesting perspective to improve cargo trafﬁcking in cellulo and in vivo.
Acknowledgements
This work was supported in part by the Centre National de la
Recherche Scientiﬁque (CNRS), and by grants from the ANR (Agence
Nationale de la Recherche, ANR-06-BLAN-0071), and the European
Community (QLK2-CT-2001-01451). We thank May C. Morris (CRBM-
UMR5237-CNRS) for the critical reading of the manuscript and all
members of the laboratory and our collaborators for the fruitful
discussions.References
[1] F. Heitz, M.C. Morris, G. Divita, Twenty years of cell-penetrating peptides:
from molecular mechanisms to therapeutics, Br. J. Pharmacol. 157 (2009)
195–206.
[2] M. Zorko, U. Langel, Cell-penetrating peptides: mechanism and kinetics of cargo
delivery, Adv. Drug Deliv. Rev. 57 (2005) 529–545.
[3] G.P. Dietz, M. Bahr, Delivery of bioactive molecules into the cell: the Trojan horse
approach, Mol. Cell. Neurosci. 27 (2004) 85–131.
[4] R. Fischer, M. Fotin-Mleczek, H. Hufnagel, R. Brock, Break on through to the other
side-biophysics and cell biology shed light on cell-penetrating peptides, Chem.
Biochem. 6 (2005) 2126–2142.
[5] Ü. Langel, in: Ü. Langel (Ed.), Cell-Penetrating Peptides: Processes and Applica-
tions, CRC Press, Boca Raton, 2002.
[6] J.P. Richard, K. Melikov, E. Vives, C. Ramos, B. Verbeure, M.J. Gait, L.V. Chernomordik,
B. Lebleu, Cell-penetrating peptides. A reevaluation of the mechanism of cellular
uptake, J. Biol. Chem. 278 (2003) 585–590.
[7] D. Derossi, S. Calvet, A. Trembleau, A. Brunissen, G. Chassaing, A. Prochiantz, Cell
internalization of the third helix of the Antennapedia homeodomain is receptor-
independent, J. Biol. Chem. 271 (1996) 18188–18193.
[8] H. Binder, G. Lindblom, Charge-dependent translocation of the Trojan peptide
penetratin across lipid membranes, Biophys. J. 85 (2003) 982–995.
[9] S. Deshayes, T. Plenat, P. Charnet, G. Divita, G. Molle, F. Heitz, Formation of
transmembrane ionic channels of primary amphipathic cell-penetrating peptides.
Consequences on the mechanism of cell penetration, Biochim. Biophys. Acta 1758
(2006) 1846–1851.
[10] S.T. Henriques, M.A. Castanho, Consequences of nonlytic membrane perturbation
to the translocation of the cell penetrating peptide pep-1 in lipidic vesicles,
Biochemistry 43 (2004) 9716–9724.
[11] A.T. Jones, Macropinocytosis: searching for an endocytic identity and role in the
uptake of cell penetrating peptides, J. Cell. Mol. Med. 11 (2007) 670–684.
[12] I.M. Kaplan, J.S. Wadia, S.F. Dowdy, Cationic Tat peptide transduction domain
enters cells by macropinocytosis, J. Control. Release 102 (2005) 247–253.
[13] J.P. Richard, K. Melikov, H. Brooks, P. Prevot, B. Lebleu, L.V. Chernomordik, Cellular
uptake of unconjugated TAT peptide involves clathrin dependent endocytosis and
heparan sulfate receptors, J. Biol. Chem. 280 (2005) 15300–15306.
[14] T. Letoha, S. Gaal, C. Somlai, A. Czajlik, A. Perczel, B. Penke, Membrane trans-
location of penetratin and its derivatives in different cell lines, J. Mol. Recognit.
(2003) 272–279.
[15] J.J. Wadia, R.V. Stan, S. Dowdy, Transducible TAT-HA fusogenic peptide enhances
escape of TAT-fusion proteins after lipid raft macropinocytosis, Nat. Med. 10
(2004) 310–315.
[16] I. Nakase, A. Tadokoro, N. Kawabata, T. Takeuchi, H. Katoh, K. Hiramoto, M.
Negishi, M. Nomizu, Y. Sugiura, S. Futaki, Interaction of arginine-rich peptides
with membrane-associated proteoglycans is crucial for induction of actin
organization and macropinocytosis, Biochemistry 246 (2007) 492–501.
[17] K. Padari, P. Saalik, M. Hansen, K. Koppel, R. Raid, U. Langel, M. Pooga, Cell
transduction pathways of transportans, Bioconjug. Chem. 16 (2005) 1399–1410.
[18] S. Deshayes, M. Decaffmeyer, R. Brasseur, A. Thomas, Structural polymorphism of
two CPP: an important parameter of activity, Biochim. Biophys. Acta 1778 (2008)
1197–1205.
[19] C. El Amri, P. Nicolas, Plasticins: membrane-damaging peptides with “chameleon-
like” properties, Cell. Mol. Life Sci. 65 (2008) 895–909.
[20] M. Mano, A. Henriques, A. Paiva, M. Prieto, F. Gavilanes, S. Simões, M.C. Pedroso de
Lima, Interaction of S413-PV cell penetrating peptide with model membranes:
relevance to peptide translocation across biological membranes, J. Pept. Sci. 13
(2007) 301–313.
[21] K. Konate, L. Crombez, S. Deshayes, A. Thomas, R. Brasseur, G. Aldrian-Herrada, F. Heitz,
G. Divita, Insight into the cellular uptake mechanism of a secondary amphipathic
cell penetrating peptide for siRNA delivery, Biochemistry 49 (2010) 3393–3402.
[22] E. Eiríksdóttir, K. Konate, Ü. Langel, G. Divita, S. Deshayes, Secondary structure of
cell-penetrating peptides controls membrane interaction and insertion, Biochim.
Biophys. Acta 1798 (2010) 1119–1128.
[23] S. El-Andaloussi, T. Holm, Ü. Langel, Cell-penetrating peptides: mechanism and
applications, Curr. Pharm. Des. 11 (2005) 3597–3611.
[24] M.C. Morris, S. Deshayes, F. Heitz, G. Divita, Cell-penetrating peptides: from
molecular mechanisms to therapeutics, Biol. Cell 100 (2008) 201–217.
[25] S. Deshayes,M.C.Morris, F. Heitz, G. Divita, Delivery of proteins andnucleic acids using
a non-covalent peptide-based strategy, Adv. Drug Deliv. Rev. 260 (2008) 537–547.
[26] C.L. Murriel, S.F. Dowdy, Inﬂuence of protein transduction domains on intra-
cellular delivery of macromolecules, Expert Opin. Drug Deliv. 3 (2006) 739–746.
[27] E. Gros, S. Deshayes, M.C. Morris, G. Aldrian-Herrada, J. Depollier, F. Heitz, G.
Divita, A non-covalent peptide-based strategy for protein and peptide nucleic acid
delivery, Biochim. Biophys. Acta 1758 (2006) 384–393.
[28] B.R. Meade, S.F. Dowdy, Exogenous siRNA delivery using peptide transduction
domains/cell penetrating peptides, Adv. Drug Deliv. Rev. 59 (2007) 134–140.
[29] L. Crombez,M.C.Morris, S. Deshayes, F. Heitz, G. Divita, Peptide-basednanoparticle
for ex vivo and in vivo drug delivery, Curr. Pharm. Des. 14 (2008) 3656–3665.
[30] C. Foerg, H.P. Merkle, On the biomedical promise of cell penetrating peptides:
limits versus prospects, J. Pharm. Sci. 97 (2008) 144–162.
[31] M.Mano, C. Teodósio, A. Paiva, S. Simões, M.C. Pedroso de Lima, On themechanisms
of the internalization of S4(13)-PV cell-penetrating peptide, Biochem. J. 390 (2005)
603–612.
[32] M.C. Morris, P. Vidal, L. Chaloin, F. Heitz, G. Divita, A new peptide vector for
efﬁcient delivery of oligonucleotides into mammalian cells, Nucleic Acids Res. 25
(1997) 2730–2736.
2314 S. Deshayes et al. / Biochimica et Biophysica Acta 1798 (2010) 2304–2314[33] M.C. Morris, J. Depollier, J. Mery, F. Heitz, G. Divita, A peptide carrier for the
delivery of biologically active proteins into mammalian cells, Nat. Biotechnol. 19
(2001) 1173–1176.
[34] S. Deshayes, M.C. Morris, G. Divita, F. Heitz, Cell penetrating peptides: a tool for
therapeutics delivery, Cell. Mol. Life Sci. 62 (2005) 1839–1849.
[35] L. Crombez, G. Aldrian-Herrada, K. Konate, Q.N. Nguyen, G.K. McMaster, R.
Brasseur, F. Heitz, G. Divita, A new potent secondary amphipathic cell-penetrating
peptide for siRNA delivery into mammalian cells, Mol. Ther. 17 (2009) 95–103.
[36] A. Eguchi, B.R. Meade, Y.C. Chang, C.T. Fredrickson, K. Willert, N. Puri, S.F. Dowdy,
Efﬁcient siRNA delivery into primary cells by a peptide transduction domain-
dsRNA binding domain fusion protein, Nat. Biotechnol. 27 (2009) 567–571.
[37] W.J. Kim, L.V. Christensen, S. Jo, J.W. Yockman, J.H. Jeong, Y.H. Kim, S.W. Kim,
Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA
effectively inhibits tumor growth in colon adenocarcinoma, Mol. Ther. 14 (2006)
343–350.
[38] P. Kumar, H. Wu, J.L. McBride, K.E. Jung, M.H. Kim, B.L. Davidson, S.K. Lee, P.
Shankar, N. Manjunath, Transvascular delivery of small interfering RNA to the
central nervous system, Nature 448 (2007) 39–43.
[39] M. Pooga, C. Kut, M. Kihlmark, M. Hällbrink, S. Fernaeus, R. Raid, T. Land, E.
Hallberg, T. Bartfai, U. Langel, Cellular translocation of proteins by transportan,
FASEB J. 15 (2001) 1451–1453.
[40] P. Lundberg, S. El Andaloussi, T. Sütlü, H. Johansson, Ü. Langel, Delivery of short
interfering RNA using endosomolytic cell-penetrating peptides, FASEB J. 21
(2007) 2664–2671.
[41] M. Mäe, S. EL Andaloussi, P. Lundin, N. Oskolkov, H.J. Johansson, P. Guterstam, Ü.
Langel, A stearylated CPP for delivery of splice correcting oligonucleotides using a
non-covalent co-incubation strategy, J. Control. Release 134 (2009) 221–227.
[42] M.C. Morris, L. Chaloin, J. Méry, F. Heitz, G. Divita, A novel potent strategy for gene
delivery using a single peptide vector as a carrier, Nucleic Acids Res. 27 (1999)
3510–3517.
[43] K. Rittner, A. Benavente, A. Bompard-Sorlet, F. Heitz, G. Divita, R. Brasseur, E.
Jacobs, New basic membrane-destabilizing peptides for plasmid-based gene
delivery in vitro and in vivo, Mol. Ther. 5 (2002) 104–114.
[44] S. Gottschalk, J.T. Sparrow, J. Hauer, M.P. Mims, F.E. Leland, S.L. Woo, L.C. Smith, A
novel DNA–peptide complex for efﬁcient gene transfer and expression in
mammalian cells, Gene Ther. 3 (1996) 448–457.
[45] F. Simeoni, M.C. Morris, F. Heitz, G. Divita, Insight into the mechanism of the
peptide-based gene delivery system MPG: implications for delivery of siRNA into
mammalian cells, Nucleic Acids Res. 31 (2003) 2717–2724.
[46] J. Méry, C. Granier, M. Juin, J. Brugidou, Disulﬁde linkage to polyacrylic resin for
automated Fmoc peptide synthesis. Immunochemical applications of peptide
resins and mercaptoamide peptides, Int. J. Pept. Protein Res. 42 (1993) 44–52.
[47] M.C. Morris, E. Gros, G. Aldrian-Herrada, M. Choob, J. Archdeacon, F. Heitz, G.
Divita, A non-covalent peptide-based carrier for in vivo delivery of DNA mimics,
Nucleic Acids Res. 35 (7) (2007) e49.
[48] S. Deshayes, S. Gerbal-Chaloin, M.C. Morris, G. Aldrian-Herrada, P. Charnet, G.
Divita, F. Heitz, On the mechanism of non-endosomial peptide-mediated cellular
delivery of nucleic acids, Biochim. Biophys. Acta 1667 (2004) 141–147.
[49] L. Kurzawa, M. Pellerano, M.C. Morris, PEP and CADY-mediated delivery of
ﬂuorescent peptides and proteins into living cells, Biochim. Biophys. Acta (2010)
Feb 25. (Epub).
[50] L. Crombez,M.C.Morris, S. Dufort, G. Aldrian-Herrada, Q. Nguyen, G.McMaster, J.L.
Coll, F. Heitz, G. Divita, Targeting cyclin B1 through peptide-based delivery of
siRNA prevents tumour growth, Nucleic Acids Res. 37 (2009) 4559–4569.
[51] S. Deshayes, A. Heitz, M.C. Morris, P. Charnet, G. Divita, F. Heitz, Insight into the
mechanism of internalization of the cell-penetrating carrier peptide Pep-1
through conformational analysis, Biochemistry 43 (2004) 1449–1457.[52] M.A. Muñoz-Morris, F. Heitz, G. Divita, M.C. Morris, The peptide carrier Pep-1 forms
biologically efﬁcient nanoparticle complexes, Biochem. Biophys. Res. Commun. 355
(2007) 877–882.
[53] S. Deshayes, T. Plénat, G. Aldrian-Herrada, G. Divita, C. Le Grimellec, F. Heitz,
Primary amphipathic cell-penetrating peptides: structural requirements and
interactions with model membranes, Biochemistry 43 (2004) 7698–7706.
[54] L. Chaloin, P. Vidal, A. Heitz, N. Van Mau, J. Méry, G. Divita, F. Heitz, Conformations
of primary amphipathic carrier peptides in membrane mimicking environments,
Biochemistry 36 (1997) 11179–11187.
[55] C. Peetla, A. Stine, V. Labhasetwar, Biophysical interactions with model lipid
membranes: applications in drug discovery and drug delivery, Mol. Pharm. 6 (2009)
1264–1274.
[56] M. Magzoub, A. Gräslund, Cell-penetrating peptides: small from inception to
application, Q. Rev. Biophys. 37 (2004) 147–195.
[57] R. Maget-Dana, The monolayer technique: a potent tool for studying the
interfacial properties of antimicrobial and membrane-lytic peptides and their
interactions with lipid membranes, Biochim. Biophys. Acta 1462 (1999) 109–140.
[58] H. Brockman, Lipid monolayers: why use half a membrane to characterize
protein–membrane interactions? Curr. Opin. Struct. Biol. 9 (1999) 438–443.
[59] P. Calvez, S. Bussières, E. Demers, C. Salesse, Parameters modulating themaximum
insertion pressure of proteins and peptides in lipid monolayers, Biochimie 91
(2009) 718–733.
[60] J.R. Couchman, Syndecans: proteoglycan regulators of cell-surface microdomains?
Nat. Rev. Mol. Cell Biol. 4 (2003) 926–937.
[61] G.M. Poon, J. Gariépy, Cell-surface proteoglycans as molecular portals for
cationic peptide and polymer entry into cells, Biochem. Soc. Trans. 35 (2007)
788–793.
[62] P. Lundin, H. Johansson, P. Guterstam, T. Holm, M. Hansen, Ü. Langel, S. El
Andaloussi, Distinct uptake routes of cell-penetrating peptide conjugates,
Bioconjug. Chem. 19 (2008) 2535–2542.
[63] A. Ziegler, J. Seelig, Binding and clustering of glycosaminoglycans: a common
property of mono- and multivalent cell-penetrating compounds, Biophys. J. 94
(2008) 2142–2149.
[64] S. Gerbal-Chaloin, C. Gondeau, G. Aldrian-Herrada, F. Heitz, C. Gauthier-Rouvière,
G. Divita, First step of the cell-penetrating peptide mechanism involves Rac1
GTPase-dependent actin-network remodeling, Biol. Cell 99 (2007) 223–238.
[65] X. Zhang, Y. Jin, M.R. Plummer, S. Pooyan, S. Gunaseelan, P.J. Sinko, Endocytosis
and membrane potential are required for HeLa cell uptake of R.I.-CKTat9, a retro-
inverso Tat cell penetrating peptide, Mol. Pharm. 6 (2009) 836–848.
[66] J.B. Rothbard, T.C. Jessop, R.S. Lewis, B.A. Murray, P.A. Wender, Role of membrane
potential and hydrogen bonding in the mechanism of translocation of guanidi-
nium-rich peptides into cells, J. Am. Chem. Soc. 126 (2004) 9506–9507.
[67] A. Ziegler, Thermodynamic studies and binding mechanisms of cell-penetrating
peptides with lipids and glycosaminoglycans, Adv. Drug Deliv. Rev. 60 (2008)
580–597.
[68] L. Chaloin, E. Dé, P. Charnet, G. Molle, F. Heitz, Ionic channels formed by a primary
amphipathic peptide containing a signal peptide and a nuclear localization
sequence, Biochim. Biophys. Acta 1375 (1998) 52–60.
[69] M. Montal, P. Mueller, Formation of bimolecular membranes from lipid
monolayers and a study of their electrical properties, Proc. Natl. Acad. Sci. U. S.
A. 69 (1972) 3561–3566.
[70] R. Fischer, M. Fotin-Mleczek, H. Hufnagel, R. Brock, Break on through to the other
side-biophysics and cell biology shed light on cell-penetrating peptides,
Chembiochem 6 (2005) 2126–2142.
[71] P.F. Almeida, A. Pokorny, Mechanisms of antimicrobial, cytolytic, and cell-
penetrating peptides: from kinetics to thermodynamics, Biochemistry 48 (2009)
8083–8093.
